NCT03091192 2026-04-14Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT02964078 2026-04-02Interleukin-2 and Pembrolizumab for Metastatic Kidney CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Completed27 enrolled 10 charts